Global Retirement Partners LLC Takes $4.10 Million Position in Abbott Laboratories $ABT

Posted by Brian Himes on Aug 27th, 2026

Global Retirement Partners LLC purchased a new position in Abbott Laboratories (NYSE:ABT – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 45,148 shares of the healthcare product maker’s stock, valued at approximately $4,097,000.

Other large investors also recently added to or reduced their stakes in the company. Freemont Management S.A. increased its holdings in Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock worth $1,341,000 after purchasing an additional 7,100 shares during the period. PFA Pension Forsikringsaktieselskab bought a new stake in Abbott Laboratories during the 4th quarter valued at $116,580,000. Thrivent Financial for Lutherans grew its stake in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares during the last quarter. Aureus Asset Management LLC raised its stake in shares of Abbott Laboratories by 25.0% during the 1st quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after acquiring an additional 66,422 shares in the last quarter. Finally, North Dakota State Investment Board purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at $7,439,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $130.00 target price on shares of Abbott Laboratories in a research note on Friday, July 17th. TD Cowen upped their target price on Abbott Laboratories from $115.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday. BTIG Research upped their price objective on Abbott Laboratories from $131.00 to $134.00 and gave the stock a “buy” rating in a research report on Friday, July 17th. Bank of America cut their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a report on Friday, June 12th. Finally, Robert W. Baird initiated coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $119.50.

View Our Latest Analysis on Abbott Laboratories

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketone levels. The device is intended to help detect rising ketones associated with diabetic ketoacidosis and integrates with Abbott’s Libre app, digital-health ecosystem and compatible automated insulin-delivery systems. The approval strengthens Abbott’s continuous glucose-monitoring franchise and could expand its addressable market. Reuters FDA authorization article
Positive Sentiment: TD Cowen raised its price target for ABT from $115 to $135 and maintained a “buy” rating, implying approximately 18% upside from the referenced $114.11 level. The target increase reflects confidence in Abbott’s growth prospects and valuation relative to peers. Benzinga analyst price target report
Neutral Sentiment: Industry forecasts identify Abbott as a participant in expanding atrial-fibrillation treatment and device markets, particularly pulsed-field ablation, mapping catheters and left-atrial-appendage closure. These reports point to long-term opportunity but do not provide new Abbott-specific financial guidance. Atrial fibrillation treatment devices market report
Negative Sentiment: Abbott agreed to pay $670 million to settle claims that its specialized premature-infant formula contributed to necrotizing enterocolitis. The settlement removes some litigation uncertainty but highlights continuing legal and financial risks. Abbott formula claims settlement article

Abbott Laboratories Price Performance

NYSE:ABT opened at $114.11 on Thursday. The stock has a 50 day moving average of $101.66 and a two-hundred day moving average of $100.13. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The firm has a market cap of $197.45 billion, a P/E ratio of 36.93, a price-to-earnings-growth ratio of 2.25 and a beta of 0.59.

Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The company had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.The firm’s revenue for the quarter was up 13.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.26 EPS. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were given a dividend of $0.63 per share. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.2%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 81.55%.

Abbott Laboratories Profile

(Free Report)

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.